Product Details

Verpanto-L Capsules combine a proton pump inhibitor with a prokinetic agent for the comprehensive management of gastroesophageal reflux and related motility disorders. Specifically, each capsule delivers Pantoprazole Sodium IP equivalent to 40mg Pantoprazole together with 75mg Levosulpiride. As a result, it offers combined acid suppression and improved gastric motility in a single formulation.

The capsules combine:

• Pantoprazole Sodium IP (equivalent to Pantoprazole 40mg) – A proton pump inhibitor that irreversibly blocks the H+/K+-ATPase enzyme in gastric parietal cells. Consequently, it suppresses gastric acid secretion, relieving symptoms of acid reflux and supporting healing of the oesophageal lining.
• Levosulpiride (75mg) – A prokinetic agent and dopamine D2 receptor antagonist that enhances gastric motility and accelerates gastric emptying. As a result, it complements acid suppression by addressing the underlying motility component of reflux and dyspepsia.

Physicians prescribe Verpanto-L for the management of gastroesophageal reflux disease (GERD) accompanied by symptoms of delayed gastric emptying, bloating, or functional dyspepsia. In addition, its combined mechanism addresses both acid-related and motility-related components of upper gastrointestinal symptoms. Because of this profile, Verpanto-L suits gastroenterology and general practice settings managing complex reflux and dyspeptic conditions.

Key Features:

• Overall, this combination formulation guarantees pharmaceutical-grade purity across both actives
• Additionally, the dual-mechanism formula addresses both acid suppression and gastric motility
• Furthermore, each capsule delivers precise, validated dosage accuracy at 40mg + 75mg
• Notably, rigorous quality testing backs every stage of manufacturing
• Beyond that, blister packaging protects capsule integrity against light
• Ultimately, a reliable supply chain suits bulk distribution to hospitals, clinics, and pharmacies